🇺🇸 FDA
Pipeline program

626

SSGJ-626-SLE-Ib/II-01

Phase 2 small_molecule active

Quick answer

626 for Systemic Lupus Erythematosus (SLE) is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials